Healthy Volunteers Clinical Trial
Official title:
Diet-Induced-Obesity Resistant Phenotypes in Humans
Verified date | October 22, 2012 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Obesity is the result of many factors, including genetics and lifestyle, such as
over-eating high-calorie foods and not being physically active. Obesity affects approximately
one third of adults in the United States. Researchers often study individuals who are already
overweight and obese, but another approach is to examine people who stay thin despite eating
whatever they want and not exercising. Studying these thin individuals will enhance
understanding of why some people become obese and others do not, which may lead to novel
treatments for obesity.
Objective:
- To study the metabolism, body composition, body temperature, physical activity, and blood
chemistries of healthy lean adults before and after adding 1,000 extra Calories per day to
their normal diet.
Eligibility:
- Healthy adults, 30 to 50 years of age, who have never been overweight after adolescence,
who are currently weight-stable, sedentary, and eating without restrictions.
Design:
- The entire study will take about 9 weeks and will include the following outpatient and
inpatient visits:
<TAB>- Outpatient screening visit and monitoring: Physical examination and blood test at
screening; then, one week of physical activity monitoring (e.g., with a pedometer-like device
called an accelerometer) and completing a food diary.
<TAB>- Baseline inpatient visit (5 days): Volunteers will eat a normal diet to maintain body
weight. Energy expenditure, body composition, physical fitness, activity level, and eating
behavior will be measured. Urine and blood samples will be taken. Volunteers may go home for
the weekend or stay at the metabolic clinical research unit (MCRU).
<TAB>- Inpatient feeding week 1 (5 days): Volunteers will eat a normal diet plus milkshakes
for added calories. All the same measurements during the baseline week visit will be
repeated.
<TAB>- Outpatient feeding weeks 2 3: Volunteers will eat breakfast at the MCRU everyday for
the next 2 weeks and take prepared meals home with them (volunteers may also stay at the MCRU
for the 2 weeks if they prefer). Volunteers will drink a non-radioactive (heavy) water called
doubly labeled water to measure energy expenditure in their normal living environment Daily
urine samples will be collected.
<TAB>- Inpatient feeding week 4 (5 days): Volunteers will continue eating a normal diet plus
milkshakes for added calories. This stay and measurement is identical to inpatient feeding
week 1.
- Volunteers will be contacted at 6 and 12 months to assess any changes in body weight, diet,
and physical activity.
Status | Terminated |
Enrollment | 9 |
Est. completion date | October 22, 2012 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 50 Years |
Eligibility |
- INCLUSION CRITERIA: 1. Healthy normal men and women between 25-50 years of age; 2. BMI between 18.5 and 25.0 kg/M(2); 3. Self-reported as having had trouble gaining weight, who doing little or no exercise, self-described or by friends or family members as an overeater, and who have never tried to lose weight. EXCLUSION CRITERIA: 1. A self-reported history of overweight after the age of 18, other than during pregnancy for women; 2. Recent weight changes >2% of current body weight in the last 6 months; 3. Current or past history of eating disorders such as binge eating, anorexia nervosa, or bulimia, by psychological evaluations; 4. Current or past history of intentional weight loss by self-report, other than postpartum weight loss; 5. High physically demanding occupations or volitional exercise >20 total minutes/day of moderate intensity or higher (as measured by sweating), >2 days/week, by self-report; 6. Significant dietary limitations (multiple food allergies/intolerances, vegan diet, etc.) that may affect absorption and body weight, or special dietary requirements that are difficult to accommodate with by study diets; 7. Significant physical limitations that may preclude completing the majority of the tests in this study; 8. Current pregnancy, recent pregnancy (<3 years), current/recent breast feeding (<1 year), or perimenopausal status. During the study, women may be asked to use birth control and will undergo repeated pregnancy testing. Subjects who refuse these tests will be excluded; 9. Current or past medical conditions that are known to affect energy metabolism and body weight regulations, including HIV/AIDS, cancer, cardiac ischemia, dyslipidemia, thyroid and parathyroid disorders, hypo- or hypertension, diabetes (type 1 or type 2) or impaired glucose tolerance, congenital or acquired lipodystrophy, hepatic, renal, neuromuscular, celiac disease and other malabsorptive conditions, known genetic disorders that alter lipid metabolism, or cardiac failure as assessed by history and physical exam; 10. Any psychiatric condition (including psychosis) or personality disorder as judged by the PI or Co-PI that would impede participation in the study; 11. Smoking (currently or within the past year), excessive caffeine (>500 mg/day) and/or alcohol intake (>2 drinks/day for men, > 1 drink/day for women), as assessed by self reports and serum thiocyanate; 12. Taking narcotics, cocaine, or marijuana which would alter metabolism (positive urine toxicology screen) 13. Any use of medications or nutritional supplements known to increase EE, depress food intake, or affect absorption; 14. Unwilling or unable to give informed consent; 15. Any other clinical or sub-clinical conditions not mentioned above that are considered by the investigators as significant exclusions for the study. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Coleman DL. Obesity genes: beneficial effects in heterozygous mice. Science. 1979 Feb 16;203(4381):663-5. — View Citation
Comuzzie AG, Allison DB. The search for human obesity genes. Science. 1998 May 29;280(5368):1374-7. Review. — View Citation
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006 Apr 5;295(13):1549-55. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |